Pregabalin Capsule
Product Images NDC 68788-7527

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-7527). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Caps 200mg 90s Count

Pregabalin Capsules 200 mg, oral capsules, generic for Lyrica, labeled by Preferred Pharmaceuticals, Inc. The label includes dosage directions in English and Spanish, warnings, storage conditions, and manufacturer info (ScieGen Pharmaceuticals, Inc.). The capsule color is described as orange.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line chart showing percent improvement in pain from baseline on the horizontal axis versus percent of patients improved on the vertical axis. The chart compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The lines illustrate differences in patient improvement across these dosing regimens.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent improvement in pain from baseline on the horizontal axis versus the percent of patients improved on the vertical axis. Two treatment groups are compared: Pregabalin 100 mg three times a day and placebo. The graph illustrates a higher percentage of patients improved with Pregabalin compared to placebo across various levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin dosed at 300 mg, 150 mg, and 75 mg two times a day, against a placebo. Each dosage group has a distinct line pattern illustrating treatment efficacy over a range of pain improvement percentages.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing percent of patients improved against percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows that higher doses of Pregabalin correspond with a greater percentage of patients experiencing pain improvement compared to placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating the relative efficacy in pain improvement across these treatments.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart showing responder rates (%) for two clinical trials labeled Study E1 and Study E3. Each compares different dosages of pregabalin given twice daily (BID) or three times daily (TID) to placebo. The chart highlights statistically significant improvement in responder rates at various dosages versus placebo in both studies.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response curve chart depicting seizure reduction, measured as median percentage change from baseline, for four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID. The x-axis represents dose in mg/day ranging from 0 (placebo) to 600 mg/day, and the y-axis shows seizure reduction percentage up to 60%. Significant p-values are noted at multiple dose points across studies.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 800 mg, 450 mg, 300 mg, and placebo. The lines represent varying efficacy levels, with axes labeled accordingly.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve chart comparing Pregabalin and Placebo groups over 180 days. The y-axis shows the estimated percentage of subjects without LTR, and the x-axis represents time in days. Pregabalin is depicted with a solid line, showing a higher survival percentage compared to the Placebo dashed line over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line chart comparing the percent of subjects improved over a range of percent improvement from baseline to week 12 BOCF between Pregabalin and placebo groups. The Pregabalin line shows a higher percentage of subjects improved than the placebo line throughout the range displayed.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved over time from baseline to week 16, with Pregabalin and Placebo groups. The x-axis shows percent improvement from baseline to week 16 BOCF, and the y-axis shows percent of subjects improved. Two lines display trends for Pregabalin and Placebo groups, illustrating treatment effects over the study period.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A renal function calculation formula showing creatinine clearance (CLcr) based on age, weight, and serum creatinine, with an adjustment factor of 0.85 for female patients. The formula uses age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin depicted as a 2D molecular diagram showing carbon, hydrogen, nitrogen, and carboxyl groups with stereochemistry indicated, consistent with the active ingredient in the drug Pregabalin 200 mg capsules by Preferred Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.